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Abstract
Background: A special challenge for research studies of breast cancer among females is low patient participation
rates. We compiled this systematic review to identify reasons why women with, or at high risk of, breast cancer do
or do not participate in medicinal studies of breast cancer.
Method: A systematic literature search in the databases Cochrane Library, EMBASE, Medline, Pascal Biomed, ACP
Journal Club and CINAHL, as well as searches through reference lists of relevant texts, was performed.
Results: Of 39 relevant full texts, ultimately, nine studies (1 qualitative, 8 quantitative) were included after applying
the inclusion criteria. Despite a lack of data material, it was possible to identify various factors influencing women’s
willingness to participate in medicinal studies and group them into three categories: person-related, study-related,
and physician-related.
Conclusion: Reasons for or against participation in studies of medicinal therapies by women with, or at high risk
of, breast cancer are multi-dimensional, and should be considered when planning such studies to garner higher
participation rates. For a more comprehensive picture of factors that affect participation, further studies in this field
are recommended.
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Background
Recruitment of participants in breast cancer trials relative
to the incidence of breast cancer patients is somewhat
higher than in other cancer types, such as colorectal or
lung cancer [1]. However, the number of participants in
breast cancer trials is still rather low. Estimates of partici-
pation of adult persons in cancer studies is about
1.5-11% of the total number of newly diagnosed or inci-
dental cases [1,2]. Low participation in studies can lead
to under-representation, which, in turn, can result in an
effect or a clinical effectiveness being shown as not signif-
icant [3] or in a failure to obtain theoretical data satura-
tion [4]. Low participation rates in a study may also
induce bias, whereby those enrolled do not represent the
target population very well. The reason why a planned
sample size is not reached within the time frame can,
among other things, depend on problems in recruiting
participants [5]. Research studies, grouped in reviews,
have investigated possible barriers to cancer patients’ par-
ticipation in clinical studies [6-8]. Among these barriers
are, for example, randomization, preferences for a certain
therapy, degree of knowledge or additional effort in travel
[6,7].
In all of these studies however, patients with different
cancer types were combined; for example, breast cancer,
lung cancer and intestinal cancer, as well as various
therapies.
To gain a better understanding of why especially
female breast cancer patients frequently do not partici-
pate in clinical medicinal studies, a systematic review
regarding this sensitive female patient group was
conducted.
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Study type
This review includes both qualitative and quantitative
s t u d i e st h a td i s c u s sr e a s o n sa n db a r r i e r so ri n f l u e n c i n g
factors for the participation of female breast cancer
patients in medicinal studies. Clinical medicinal studies
in this paper, are defined as studies with a variety of
medical therapies, which may include, for example, che-
motherapies, endocrine therapies and immune therapies
within neo-adjuvant and adjuvant therapy [9].
Search strategy
In May 2011, a systematic literature search was carried
out in the databases: Cochrane, EMBASE, Medline,
Pascal Biomed, ACP Journal Club, and CINAHL. The
following combination of MeSh-Terms and Keywords
was chosen: #1: cancer OR tumo* OR oncolog* OR neo-
plasms; #2: willing* OR enrol* OR informed consent OR
participat*; #3: clinical and trial*; #4: medica* or drug or
pharma*; #5: breast; #6: #1 AND #2 AND #3 AND #4
AND #5.
Articles were limited to those published in the last 10
years in German or English. When uncertainties regard-
ing whether the content of the studies was suitable for
this review occurred while screening study abstracts (or
when articles did not have abstracts), the respective full
texts were procured for further evaluation. To find addi-
tional relevant literature, the reference lists of the full
texts were searched for possible articles.
Selection criteria
Inclusion criteria: studies that focused on participation
or non-participation in clinical medicinal studies of
adult women with breast cancer.
Exclusion criteria: studies that did not examine con-
sent-competent female patients, did not focus on medi-
cations, investigated the effectiveness of medications, or
did not refer to primary sources, study protocols and
commentaries.
Data evaluation
Full texts found in the literature research were evaluated
regarding methodical or theoretical rigor by means of
the applicable quality checklist for quantitative or quali-
tative studies of the Alberta Heritage Foundation for
Medical Research [10]; texts with values < .75 by these
criteria were not used.
Data analysis
The following data were extracted from the respective
full texts: objective, study type/design, method, number
and characteristics of the participants, definition of the
term “study participation,” setting, and results. These
extracted data were compared and categorized with
regard to factors influencing participation (for and
against see Table 1 and 2) in clinical medicinal studies of
women, regardless of which research area they originally
came from. This categorization was performed according
to Mills et al., 2006 [7].
Results
After applying the selection criteria according to the
title and abstract screening, 39 publications (of initially
3080 references) remained for further evaluation. Twelve
publications were excluded as secondary literature, com-
ments or protocols; 17 publications were excluded
because their focus was not of interest (e.g., medicinal
studies). One additional article was included from the
reference lists. Two articles had to be excluded as they
each had a quality score of < 0.75. Ultimately, 9 publica-
tions met the inclusion criteria and were subjected to
further analysis and evaluation (see Figure 1).
Eight of these nine included studies were quantitative
[11-18]; only one was qualitative [19]. The summarized
data extraction of the individual studies is found in
Table 3. The quality assessments performed, including
comments, are depicted in Tables 4 and 5, according to
research areas. Four of the studies were conducted in
the United States [12,13,17,19], two in Canada [11,14],
and the rest in Europe; in Germany [15], France [16]
and Italy [18]. All of these articles have been published
in English.
I nt h ea r t i c l e s ,ag r e a tv a r i e t yo fs t u d yd e s i g n sw e r e
utilized as case-control [12], cohort [16] or randomized
studies [17] (among others), where the design was not
explicitly identified in most of them [11,13-15,18,19].
The prevalent method used to elicit women’sr e a s o n s
for or against participation in studies with medicinal
therapies were questionnaires [11-13,15-18]. Most of the
articles referred to investigations already performed, to
identify the relevant reasons for consent or refusal to
participate [12,14,15,18,19]. Three studies, though, used
theoretical scenarios for the solicitation of reasons
[11,13,16]. In one article, on the other hand, women
were asked regarding their intent to participate in a
currently active study [17].
T h em a j o r i t yo ft h es t u d i e s focused on chemothera-
pies [11,12,15-17,19], whereas only one particularly
referred to endocrine therapy [18], one to a new aroma-
tase inhibitor, other endocrine therapy and chemother-
apy [14], and another one generally to medicines [13].
Half of the studies addressed post-menopausal
women, each with varying degrees of breast cancer risk
[12,15,17-19], and half of the studies addressed women
with invasive breast cancer [11,13,14,16]. The studies
mainly investigated women with an average age of 53
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Page 2 of 11(range: 40-66 years) [11-18]. One study mainly included
women in age groups 50-59, 60-69 and 70-79 years [19].
Discussion and conclusions
The various factors influencing participation in breast
cancer medicinal research identified in the nine studies
were placed by the authors into three categories: person-
related, physician-related and study-related.
The person-related category comprised health, psycho-
social and demographic reasons. A younger age (demo-
graphic reason) was identified as a factor influencing
willingness to participate [15,17,18].
Regardless of whether study participants were younger or
older, they frequently had high subjective perceptions of
their risk of breast cancer [16,18], although their objective
risks, assessed according to Gail scores, in one of the two
studies, were relatively low on average [17,19,20]. Another
study also showed women who had participated in medica-
tion studies assessed their breast cancer risk subjectively
much higher than women who had not participated,
though both groups did not differ according to their Gail
scores [19]. This suggests that, in future studies, subjective
perceptions of risk should be addressed. Also, in ovarian
cancer investigations, potential subjects’ higher personal
risk perception and concern raised the probability of mak-
ing use of screening [21,22]. These results suggest that
women’s participation in such studies depends more on
subjective risk than objective risk. Though subjective breast
cancer risk in two studies in this review correlated with the
women’s willingness to participate [17,19], in another medi-
cation study, women’s participation was more likely when
they were less personally concerned about breast cancer
[18]; however, this last-mentioned study does not reveal
whether relatives of the study participants had suffered
from breast cancer or not, which could increase the sub-
jects’ concern, and thus interest, in participating in a medi-
cation study. One study showed women who had first and
second degree relatives with breast cancer requested
Table 1 Reasons for participation in medicinal studies
Reasons for participation Statistical output
Altruism (support of medical research and/or
helping other patients)
Support of medical research or helping other people (33%, n = 8) [11]; contribution to therapeutic
knowledge (44%, n = 116) [18]; altruism in general (50%, n = 14) [19]; non-participants felt bad
due to altruistic reasons as they themselves did not contribute to the study efforts (39%, n = 9)
[19]
Wish for improvement (regarding own chances or
regular medical care)
Improve the chances for breast cancer prevention (P = 0.033; OR = 3.16; 95% CI: [1.10-9.06]) [12]; a
regular medical care (58%, n = 154) [18], wish for helping themselves (50%, n = 14) [19]
Concern of breast cancer or often thinking about
the topic of breast cancer
Cancer thoughts (P = 0.002; OR = 2.30; 95% CI: [1.40-3.80]) [17], strong concerns regarding breast
cancer (P = 0.01; OR = 0.15; 95% CI: [0.03-0.77]) [18]
Physical condition Women with non-metastasized carcinoma vs. metastasized carcinoma (RR = 2.80, P < 0.01) [14],
good-excellent vs. fair-poor health status (P = 0.05; OR = 1.47; 95% CI: [1.25-1.98]) [17]
Age 49 ± 10 vs. 54 ± 11 years (mean ± SD) (P < 0.0001; OR = 1.05; 95% CI: [1.02-1.08]) [17]; under 60
years (P = 0.003; OR = 0.40, 95% CI: [0.22-0.73]) [18]
Memory of close person(s) with breast cancer 21% (n = 6) valued their own breast cancer risk as low, but nevertheless participated in the study
out of respect or a memory of a close person who suffered from breast cancer [19]
Readiness for treatment in a study Nothing to lose by participating (33%; n = 8) [11]; general willingness (60%; n = 160) [18]
Acceptance of randomization Acceptance of randomization (P < 0.001; OR = 4.6; 95% CI: [2.7-7.7]) [16]
No placebo Placebo vs. no placebo (RR = 0.80; P = 0.05) [14]
Longer interval from diagnosis/surgery/end of
therapy until enrollment
For non-metastatic trials: if the study protocol planned an interval of 12 weeks or longer between
diagnosis/op/end of therapy and recruiting in comparison to a shorter interval (RR = 1.36; P <
0.01) [14]
Already decided once to participate in a medicinal
study
Already having decided to participate in a study (P < 0.001; OR = 5.0; 95% CI: [2.9-8.7]) [16]
Predominantly advantages through the study Perceived value of the trial (P = 0.020; OR = 2.92; 95% CI: [1.18-7.21]) [12], predominant advantages
of the study (50%, n = 14) [19]
Each treatment strategy seems helpful Each of the treatments seems to be beneficial (42%; n = 10) [11]
Idea of receiving a better treatment Idea to receive better treatment (25%; n = 6) [11]
Feeling, physicians must make decisions Medical decision-making preferences (P = 0.045; OR = 2.2; 95% CI: [1.0-4.9]) [16]
Feeling of not being able to reject physician’s
suggestion
Unable to refuse the physician’s suggestion (P = 0.031; OR = 1.8; 95% CI: [1.1-3.2]) [16]
Satisfaction with receiving information during
consultation with physician
Satisfaction with communication processes (P < 0.001; or = 3.1; 95% CI: [1.5-7.8]) [16], satisfaction
with the physician’s explanations (P < 0.001; OR = 9.33; 95% CI: [4.04-21.55]) [18]
Receiving information regarding financial conflicts
of interest
61-72% (n = 614-724) wish to receive information about financial conflicts of interest [13]. 61-84%
(n = 614-845) would participate in a medication study in spite of financial conflicts of interest [13]
Adequate medical expert knowledge or
qualification of the physician
Clinician expertise and qualifications (P = 0.012; OR = 4.9; 95% CI: [1.41-17.04]) [12]
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Page 3 of 11information about the medication study twice as often as
women who did not have this diagnosis among their rela-
tives (OR 2.35, 95% CI, 0.99-5.57)[15].
Studies show a negative correlation between the concern
regarding breast cancer and satisfaction with the physician’s
consultation [23]. Nevertheless, satisfaction with physicians’
consultation and communication processes (physician-
related reason) was mentioned as reason for participation/
non-participation in medication studies [16,18], indicating
that patient-clinician relationships play a decisive role in
patients’ willingness to participate in a study.
Identification of potential differences in consultations
in the medication studies was not possible [11,13,16]
because only one study reported the content of the con-
versations [17]. Therefore, not all women in the studies
might have been informed about the same things. To
avoid this distortion in future studies, the use and docu-
mentation of conversation manuals in these consulta-
tions seems advisable.
The main study protocol-related reason against parti-
cipation was additional time needed [12,18,19].
The randomization procedure was mentioned in two
studies as reason against participation [11,19]; willingness
for randomization was mentioned in one study as an
influencing factor for participation [16]. In cancer
research, lack of understanding of the principle of rando-
mization has been researched as barrier to subject parti-
cipation [24,25]. Another study showed that, among
those who initially decided against participation in rando-
mized studies, more than half ultimately consented to
participation after they had received more detailed infor-
mation regarding the randomization process [26].
Though this connection was not identifiable from studies
in this review, our results showed that randomization
could influence participation in medication studies.
Informing potential study subjects of the reasons for ran-
domization could therefore promote their participation.
Fear of possible side-effects (a treatment-related rea-
son) was also frequently mentioned as reason for non-
participation [11,15,18,19], suggesting that the probabil-
ities for possible side-effects should be explained exten-
sively during recruitment.
Table 2 Reasons against participation in medicinal studies
Reasons for non-participation Statistical output
Inconspicuous mammography result Inconspicuous result of a mammography (42%, n = 84) [15]
Additional chronic and/or acute sickness Current chronic or acute sickness (20%, n = 40) [15], having a higher risk of developing other diseases than
breast cancer (more than 50%, n > 14) [19]
Skepticism towards clinical studies General skepticism towards clinical studies (2%, n = 4) [15]
Feeling of becoming an “experiment” by
participating
The thought of being an experiment (10%, n = 3) [11]
Additional family problems or no family
support
Family problems (5%, n = 9) [18]
Fear of possible side effects Side effects (14%, n = 4) [11], (3%, n = 6) [15], 31% (n = 59) [18], 35% (n = 8) [19], willingness decreased
from 72% (n = 324) to 52% after explanation of side effects, and to 45% after uterine cancer was
mentioned [17]
Preference of a certain treatment form Preferences regarding chemotherapy (21%, n = 6) [11], not the same advantages as a menopausal hormone
replacement therapy (22%, n = 5) [19]
Additional time necessary Level of trial inconvenience regarding to the time requirements (P = 0.002, OR = 0.10, 95%CI [0.02-0.44])
[12], need too much time for the study (7%, n = 14) [15], additional time and effort needed (22%, n = 5)
[19]
Study lasts too long Aversion to taking tamoxifen for 5 years (14%, n = 4) [11], study duration (6%, n = 11) [18]
Too far to travel from home to place of
study
Too far to travel from home to the examination center (12%, n = 24) [15], distance (4%, n = 8) [18]
Randomization Aversion regarding the allotment of treatments in the study (38%, n = 11) or regarding the randomization
(17%, n = 5) [11], randomization (39%, n = 9) [19]
Fear of medication abuse Medication abuse (33%, n = 64) [18]
Incompatibility of own therapy and
study medication
Incompatibility of their hormone replacement therapy with the study medication (22%, n = 5) [19]
Concern of not receiving appropriate
therapy for oneself
Concern of receiving the appropriate treatment (7%, n = 2) [11]
Not willing to lose control over personal
decisions
Loss of control (7%, n = 2) [11], women who refused showed preferences regarding personal decision
making (72%) versus women who accepted (35%) (P < 0.001) [16]
Not willing to decide for oneself
regarding participation
Not want to make own decision because physician should decide (10%, n = 3) [11]
Physician’s advice not to participate Physician counsel not to participate (24%, n = 46) [18]
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Page 4 of 11The review shows that the willingness to participate in
the theoretical scenarios was considerably higher (58%;
range: 25-75%) [11,13,16] than in studies that were actu-
a l l y ,o ry e tt ob e ,c o n d u c t e d( 2 7 % ;r a n g e :1 . 5 - 5 5 % )
[12,14,15,17-19]. High willingness to participate in
hypothetical scenarios is also seen in other studies
[26-28]. Two studies collected their data retrospectively
[12,19], with the risk of recall bias in the results. Two
other studies counteracted this bias by collecting would-
be participants’ relevant reasons immediately after con-
sent or rejection of participating in their respective
study [15,18]. This procedure could also prevent such
distortion in future studies.
A limitation of this review concerns its ten-year time
frame. Although more full texts might have been included
if our criteria allowed older investigations, the primary
goal of this review was to identify current studies; we
therefore restricted this study to the past decade.
Cochrane DSR (174)  Pascal Biomed (158)    
EMBASE (1913)     ACP Journal Club 
(6) 
Medline (604)    
  CINAHL (225) 
 
Activated limits according to possibility:  
Abstract screening (133) 
Total (3080)  Exclusion of duplicates (888) 
Exclusion due to content (2059) 
(Focus not of interest: e.g., effectiveness studies, other cancer types, 
children, alternative medicine, mammography-screening) 
Title screening (2192) 
Exclusion due to content (94)   
36   Effectiveness of medications/interventions/therapies/  
       procedures/breast care management 
28   Focus /Target population not breast cancer patients 
13   Other  
10   Medical first sessions 
  7   Psycho-social: consequences of breast cancer/contentment    
studies 
Exclusion due to content (30)   
12   No primary source, comments, protocols, 
17   Focus not of interest (e.g., cancer in general or no  
     separate analysis of the results of the subjects with  
     individual cancer types, not medicinal studies) 
Full text screening (39)  
Inclusion from reference lists (1)   
Full texts in review (9)  
Exclusion due to low quality (2) 
Figure 1 Flow chart of study selection process.
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Page 5 of 11The strengths of this review include its use of an
extensive assessment scheme, allowing comprehensive
quality evaluation of the respective articles, using consis-
tent criteria. This scheme also could function as a kind
of checklist, thus reducing the probability of forgetting
any items in the assessment. Another strong point was
that six databases were searched, allowing wide coverage
of possible publications, as a result, of the articles
gleaned from the references of all the full texts, only
one was found that had not been part of the original
database literature research. Inclusion of only high-qual-
ity studies is a further strength, as all studies had to
s h o wah i g hq u a l i t y ,o fa tl e a s t7 5 % ,t ob ei n c l u d e di n
this review. Two studies did not meet this requirement
and were therefore not included in the results [29,30].
Physicians’ viewpoints as to why women with breast
cancer or breast cancer risk choose or decline to partici-
pate in medication studies is being researched, both
with regard to general cancers [31] and breast cancer
[24,32], but not specifically with medication studies.
In sum, this review shows that the reasons for partici-
pation/non-participation in medication studies are mul-
tifactorial. Moreover, while factors affecting patient
participation in medication studies are obviously useful
to know in planning and realizing future investigations,
few such insights are currently available, apparently due
Table 3 Methodological descriptions of the studies (N = 9)
Reference Country Objective/Question Design Method Participants Data
analysis
Altschuler &
Somkin
2005 [19]
USA Why did women who initially showed
interest in participating in the STAR trial
make different decisions about whether
to participate or not participate?
(tamoxifen or raloxifene)
Qualitative
chemo-
prevention
study
Half-structured
deep interviews
51 post-menopausal women
with high breast cancer risk(28
participants and 23 non-
participants)
Grounded
theory
Ellis et al
2002 [11]
Canada Evaluation of information brochure,
regarding theoretical willingness to
participate in a 6-month clinical trial for
breast cancer treatment (Tamoxifen
alone, chemotherapy alone or
combined)
Quantitative
before-after-
study
Questionnaires
closed answers
Before: 83 women with early
invasive breast cancer
After: 67 women
Descriptive
statistics
Houlihan et
al 2010 [12]
USA Investigation of factors influencing
women’s decision to participate in
breast cancer prevention trial (tamoxifen,
raloxifene).
Quantitative
case-control
study
Questionnaires
through mail
Of 242 post-menopausal
women, 81 participated
Logistic
regression
model
Kim et al
2004 [13]
USA When financial conflicts of interest were
stated on consent forms, which
respondents refused to participate in a
study using a new medication solely on
the basis of these conflicts of interest?
Quantitative
study
Internet
questionnaires;
closed answers
1006 female breast cancer
patients
Descriptive
statistics
Lemieux et
al 2008 [14]
Canada Identifying barriers in the study
protocols, with respect to the low
recruitment rates in clinical breast cancer
trials, 1997-2002.
Quantitative
study
Questionnaires;
closed answers
616 women participated in
studies of Phase III (or II+ III)
and 72 in studies of Phase II (or
I+II).
Multivariate
analysis
Loehberg et
al 2010 [15]
Germany Identification of characteristics of
women who wanted to receive
information about a Phase II
chemoprevention study.
Quantitative,
multi-
centered
study
Questionnaires 202 women of 446 wanted to
receive further information
about the risk of breast cancer;
3 women decided to
participate.
Descriptive
statistics
Mancini et
al 2007 [16]
France Identification of preferences in decision-
making processes in relation to
participation in another clinical drug
trial.
Quantitative,
prospective
cohort study
Questionnaires Of 455 women 267 were invited
to the study; of these 201
agreed to participate and 66
declined.
Descriptive
statistics and
multivariate
analysis
Mandelblatt
et al 2005
[17]
USA Effectiveness of a brief consultation and
an informational brochure compared
with use of brochure only in recruitment
for a breast cancer prevention study.
(tamoxifen and raloxifene)
Quantitative,
simple
randomized
controlled
study
Questionnaires 232 of 450 women participated
in consultation +brochure-
group; 218 of 450 in the
brochure-only-group
Descriptive
statistics and
logistical
regression
model
Rondanina
et al 2008
[18]
Italy Socio-demographic, health-related and
psychological factors influencing
decision to participate or not in a five-
year hormone replacement therapy.
(HRT-Phase III, low-dose tamoxifen)
Quantitative
study
Questionnaires
through mail
496 of 1457 women
participated in the HET-study
Descriptive
statistics and
multivariate
analysis
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Page 6 of 11Table 4 Quality assessment according to AHFMR 2004 (N = 1)
Criteria Assessment* Remarks
Altschuler & Somkin 2005 [19] (Score = 0.80**)
Research question(s)/
Objective(s)
Yes Described clearly and evident throughout the text
Study design Partially Not explicitly named; inconsistencies in subsequent data collection not evident
Study context Yes Setting is described
(Theoretical) frame of
reference
Partially Study objective does not completely follow the knowledge that is depicted in the introduction
Sampling Partially Described and reproducible; random sampling was performed until theoretical data saturation was reached;
consent of women was obtained before the interviews began. Duration of study not mentioned.
Data collection Yes Reproducible
Data analysis Yes Categories, codes, and memos described; categories listed explicitly
Reliability Yes Second author verified formation of categories/assignment of codes by the first author; if there were
discrepancies in the codes, they went back to the original material and found consensus
Conclusions Yes Results discussed; results of other studies are drawn upon as comparison
Reflexion Partially Possible influence of financial compensation were not reflected; recall bias listed as possible weakness of
the study
*Possible categories: yes, partially, no, not applicable
** Ascertainment according to AHFMR 2004 (p. 20) = ((number “yes” * 2) + (number “partially” * 1))/20
Table 5 Quality assessment according to AHFMR 2004 (N = 8)
Criteria Assessment* Remarks
Ellis et al 2002 [11] (Score = 0.71**)
Research question(s)/
Objective(s)
Yes At the beginning of the introduction; contains dependent/independent variables, including population
Study design Partially Not explicitly described, no inconsistencies in the subsequent data collection
Sampling Yes Described, exclusion criteria mentioned; written consent obtained in each case
Sample characteristics Yes Basic information given and depicted in tables
Randomization Partially Randomization performed; exact process of randomization not described
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Partially Categories of questionnaires given
Sample size Partially Power analysis performed; no information about low response rate of second questionnaire
Data analysis Partially Regression appropriate; no indication regarding the characteristics of participating/non-participating women
Variance estimate Yes Confidence intervals and ranges indicated
Confounding factor
control
Partially Control at analysis level with multivariate model, but no attempt to standardize the physician’s consultation
Result depiction Partially Described in the text; the secondary result (change of knowledge) was not depicted graphically/in a table.
Conclusions Yes Relevant results are discussed and compared with other studies
Houlihan et al 2010 [12] (Score = 0.86**)
Research question(s)/
Objective(s)
Yes Listed
Study design Yes Stated
Sampling Partially Inclusion criteria mentioned, procedure not described
Sample characteristics Partially Information only regarding city and ethnic group given; average age of the women only in Discussion
section (but without standard deviation); other basic data are not available
Randomization n.a. Not possible
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Partially Reproducible on a limited basis
Sample size Yes No power or variance analysis given; no problems with multiple tests described and significant values were
obtained
Data analysis Yes Described
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Page 7 of 11Table 5 Quality assessment according to AHFMR 2004 (N = 8) (Continued)
Variance estimate Yes Confidence intervals indicated
Confounding factor
control
Yes Control at analysis level with multivariate model
Result depiction Yes Described; significant results depicted in tables
Conclusions Yes Results depicted in a summarized manner and discussed with previous studies; limitations and recall bias
reflected
Kim et al 2004 [13] (Score = 0.75**)
Research question(s)/
Objective(s)
Yes Clearly formulated and discussed throughout the text
Study design Partially That this is a non-comparative study only becomes obvious in the results section
Sampling Partially Described; random- but convenience sample
Sample characteristics Partially Basic data exist, but not tested regarding differences between the sub-groups
Randomization Partially Would have been possible
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Yes Reproducible
Sample size Yes Variance analysis; significant values obtained
Data analysis Partially Scenarios of conflicts of interest are listed; the questions/answer options/data analysis procedure described,
results in the text do not match the table data
Variance estimate Yes Variance estimate performed
Confounding factor
control
Yes Control at analysis level with multivariate model
Result depiction Yes Results summarized and described in tables
Conclusions Partially Results discussed and compared with other studies; limits listed, possible influence on the results through
the chance of winning 3 × $500 was not reflected
Lemieux et al 2008 [14] (Score = 0.82**)
Research question(s)/
Objective(s)
Yes At the beginning of the method section; contains variables to examine, population, place and timeframe
Study design Partially Not explicitly mentioned, but no inconsistencies result in the subsequent data collection
Sampling Partially Procedure described, exclusion criteria listed; but bias possible as the selection of cooperatives and
pharmaceutical companies was made by experts
Sample characteristics Yes Basic information given, steps in the categorization mentioned
Randomization n.a. Not possible as the authors wanted to include all studies in Ontario from the years 1999-2002
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Yes Reproducible
Sample size Partially No power analysis
Data analysis Yes Poisson Regression appropriate; handling of missing values described
Variance estimate Yes Confidence intervals and ranges stated
Confounding factor
control
Partially Control at analysis level with multivariate model, but the institutions received money as incentive to
participate in the study
Result depiction Yes Results depicted in the text and tables
Conclusions Yes Results discussed and compared with other studies
Loehberg et al 2010 [15] (Score = 0.77**)
Research question(s)/
Objective(s)
Partially At the end of the introduction; calculation of influencing factors through multiple regression analyses
unclear
Study design Partially Not explicitly mentioned, no inconsistencies
Sampling Yes Procedure described, inclusion criteria mentioned
Sample characteristics Yes Basic information given
Randomization n.a. Not possible
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Partially Reproducible
Sample size Yes No power- or variance analysis given; no problems mentioned with multiple tests
Data analysis Yes Described
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Variance estimate Yes Confidence intervals and distribution indicated
Confounding factor
control
Yes Analysis of sub-groups conducted
Result depiction Partially Results depicted in the text and tables do not all follow the objective of the article, but seem to be
appropriate in general.
Conclusions Partially Results discussed and compared with other studies; no critical reflection that the information could possibly
influence the number of participants
Mancini et al 2007 [16] (Score = 1.00**)
Research question(s)/
Objective(s)
Yes Described precisely
Study design Yes Described and appropriate
Sampling Yes Procedure described; inclusion criteria mentioned; consent forms collected
Sample characteristics Yes Basic information on the women and sub-groups given;
Randomization n.a. Not possible
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Yes Reproducible
Sample size Yes No power- or variance analysis, sample size seems to be sufficiently large
Data analysis Yes Logistical regression analysis appropriate, individual tests within the framework of descriptive statistics
conducted; significance level mentioned
Variance estimate Yes Confidence intervals and standard deviations given
Confounding factor
control
Yes Control at analysis level with multivariate model
Result depiction Yes Results of regression analysis are listed in the text and table; not all significant results of the comparisons
within the framework of descriptive statistics were also described in the text, but no inconsistencies result
Conclusions Yes Results discussed and compared with other studies
Mandelblatt et al 2005 [17] (Score = 0.79**)
Research question(s)/
Objective(s)
Partially Described in the abstract, formulation of objective in the text fails to mention the investigation of two
interventions
Study design Yes Described and appropriate
Sampling Yes Procedure described; inclusion criteria mentioned; consent forms collected
Sample characteristics Yes Basic information on the women and sub-groups given
Randomization Yes Randomization performed; procedure described
Blinding: Researchers n.a. Not possible
Blinding: Participants n.a. Not possible
Data collection Yes Reproducible
Sample size Yes Not obvious whether a power analysis was conducted later; the sample size seems to be sufficient
Data analysis Partially Logistical regression analysis appropriate, tests conducted within the framework of descriptive statistic
analysis are not mentioned; handling of missing values described; significance level not given
Variance estimate Yes Confidence intervals, standard deviations and range given
Confounding factor
control
Partially Control at analysis level with multivariate model; but in asking the control group, the same standardized
questionnaire as in the intervention group was used
Result depiction Partially Secondary results depicted in the text and tables; but the primary result is not mentioned in the text, it is
only listed in the table; recording of influencing factors not conducted for both interventions. Differences
regarding the objective breast cancer risk between those women who consented to participation in the
medication study and those who refused participation were not pointed out. The text only lists percentages
and no absolute numbers; consequently, readers have to infer from the tables how many women in total
participated in the data collection, and subsequently in the medication study.
Conclusions Partially Results discussed but only partially compared with other studies
Randonina et al 2008 [18] (Score = 0.91**)
Research question(s)/
Objective(s)
Yes Appears in the middle of the method section, primary and secondary results are mentioned at the end of
the introduction
Study design Partially Not mentioned explicitly for this collection process, only the design of the medication study is described
Sampling Yes Procedure described; including criteria mentioned; consent forms collected
Sample characteristics Yes Basic information on the women and sub-groups given
Randomization n.a. Not possible
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Page 9 of 11to the small number of relevant studies; further quanti-
tative and qualitative research is needed.
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